<DOC>
	<DOC>NCT02680379</DOC>
	<brief_summary>The purpose of this study is to determine whether Lovastatin, Minocycline and the combination Lovastatin/Minocycline are effective in treating behavioral symptoms in Fragile X individuals.</brief_summary>
	<brief_title>Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<criteria>Must have a molecular diagnosis for fragile X syndrome The participant must be accompanied by his sponsor who may be the person having parental authority, his tutor (for minor) or representative (for major inapt) Identify a caregiver who spends at least six hours per day with the participant. The sponsor and the caregiver may be the same person Intelligence quotient (IQ) &lt; 70 ABCC &gt; 20 CGIS â‰¥ 4 Pregnant or breastfeeding subjects Intolerance / allergy previous to statins, minocycline or tetracycline Taking lovastatin or taking minocycline in the last 12 weeks Personal history of myopathy, myalgia or high creatine kinase (CK) level Renal disease / liver / hepatorenal balance disturbed, as antinuclear antibody (ANA) &gt; 40 Concomitant use of prohibited drugs * Taking two or more psychoactive medications except anticonvulsants Untreated hypothyroidism and / or uncontrolled Any other active medical condition Amendment psychoactive treatment in the last 6 weeks prior to randomization * Prohibited drugs include other hypolipemic including gemfibrozil (or other fibrates) and niacin (nicotinic acid), angiotensin converting enzyme (ACE), cyclosporine, danazol, amiodarone, verapamil and inhibitors P450 (CYP3A4) (itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, inhibitors of HIV protease and nefazodone).</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Fragile X Syndrome</keyword>
	<keyword>Autism</keyword>
	<keyword>FMR1</keyword>
	<keyword>FRAXA</keyword>
</DOC>